Black Diamond Therapeutics shares rise 1.75% premarket after reporting a narrower Q2 net loss and exploring partnerships for silevertinib development.

Black Diamond Therapeutics, Inc. rose 1.75% in premarket trading. The company reported a narrowing of its Q2 net loss to $10.6 million from $19.9 million year-over-year, and it is exploring partnerships to advance the development of silevertinib in NSCLC and GBM. The company expects to release Q4 2025 data for the silevertinib Phase 2 trial and plans an FDA meeting in the first half of 2026 for the NSCLC path. Additionally, Black Diamond is exploring partnerships for the pivotal development of silevertinib and sees cash funding operations into Q4 2027.